EUVIMEDDescoperă EUVIMED
Übersichtsarbeit

Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data

Xuerui Song iD, Zhi Chen, Yunfei An, Jie Zhang

British Journal of Pharmacology · 2026-07-09

DOI: 10.1111/bph.70592 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-07-09. Written by Xuerui Song and 3 co-authors. Institution: Department of Child Health Care, Xi'an Children's Hospital, Xi'an, China. 61 references. Funded by: Xi'an Children's Hospital.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Artificial intelligence (AI) is evolving from a predictive tool into a foundational computational infrastructure for mechanism‐driven pharmacology, fundamentally reshaping drug discovery. This review examines how this transformation addresses persistent challenges in target validation, including data biases and the need for model interpretability, by integrating network pharmacology with advanced deep learning architectures. Specifically, graph neural networks decipher the complex topology of biological systems and transformer models facilitate the fusion of multimodal data, from genomics to real‐world clinical records. Coupled with physics‐informed neural networks, this integrated framework operates as a predictive computational microscope. It enables comprehensive in silico simulations that span multiple biological scales, encompassing atomic‐level molecular interactions and longitudinal patient trajectories. We demonstrate that this AI‐driven paradigm is essential for advancing precision medicine, as it systematically translates vast and heterogeneous datasets into testable mechanistic hypotheses. Consequently, this approach accelerates the development of safer, more effective and patient‐specific therapies, by de‐risking target validation and elucidating novel therapeutic mechanisms. It directly addresses some of the most pressing inefficiencies in contemporary drug discovery and development, offering a pathway towards more rational and efficient therapeutic innovation.

Subjects

Author keywords

artificial intelligencegraph neural networksnetwork pharmacologyprecision medicinetarget validation

Authors and institutions

  • Department of Child Health Care, Xi'an Children's Hospital, Xi'an, China.
  • School of Computer Science, Northwestern Polytechnical University, Xi'an, China.
  • Pediatric Immunology and Rheumatology Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection…
  • Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China.

ORCID profiles: Xuerui Song

Funding

  • Xi'an Children's Hospital

Cite

APA

Song, X., Chen, Z., An, Y., & Zhang, J. (2026). Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data. British Journal of Pharmacology. https://doi.org/10.1111/bph.70592

Vancouver

Song X, Chen Z, An Y, Zhang J. Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data. British Journal of Pharmacology. 2026. doi:10.1111/bph.70592

BibTeX
@article{Song2026,
  author = {Song, Xuerui and Chen, Zhi and An, Yunfei and Zhang, Jie},
  title = {Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70592}
}
Start for free →